Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.

Watz H, Sciurba FC, Bonini M, Yañez A, Bourdin A, Zheng J, De Soyza A, Janssens W, van den Berge M, Xu JF, Saraiva GL, Jenkins M, Jimenez E, Lofdahl M, Li J, Mikosz M, Kishishita N, Jackson S, Johnson S, Patel R, Fagerås M, Psallidas I

Open source

DOI: 10.1136/bmjresp-2026-004145
Published: 2026 Jul 20
Container: BMJ open respiratory research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjresp-2026-004145,
  title = {Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.},
  author = {Watz H and Sciurba FC and Bonini M and Yañez A and Bourdin A and Zheng J and De Soyza A and Janssens W and van den Berge M and Xu JF and Saraiva GL and Jenkins M and Jimenez E and Lofdahl M and Li J and Mikosz M and Kishishita N and Jackson S and Johnson S and Patel R and Fagerås M and Psallidas I},
  year = {2026},
  journal = {BMJ open respiratory research},
  doi = {10.1136/bmjresp-2026-004145},
  url = {https://doi.org/10.1136/bmjresp-2026-004145}
}

RIS

TY  - JOUR
TI  - Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.
AU  - Watz H
AU  - Sciurba FC
AU  - Bonini M
AU  - Yañez A
AU  - Bourdin A
AU  - Zheng J
AU  - De Soyza A
AU  - Janssens W
AU  - van den Berge M
AU  - Xu JF
AU  - Saraiva GL
AU  - Jenkins M
AU  - Jimenez E
AU  - Lofdahl M
AU  - Li J
AU  - Mikosz M
AU  - Kishishita N
AU  - Jackson S
AU  - Johnson S
AU  - Patel R
AU  - Fagerås M
AU  - Psallidas I
PY  - 2026
JO  - BMJ open respiratory research
DO  - 10.1136/bmjresp-2026-004145
UR  - https://doi.org/10.1136/bmjresp-2026-004145
ER  -

APA

H, W., FC, S., M, B., A, Y., A, B., J, Z., A, D. S., W, J., M, V. D. B., JF, X., GL, S., M, J., E, J., M, L., J, L., M, M., N, K., S, J., S, J., R, P., M, F., & I, P. (2026). Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.. BMJ open respiratory research. https://doi.org/10.1136/bmjresp-2026-004145

Source records

pubmed · retrieved 2026-09-26T04:22:26.969Z